Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ProShares Ultra Nasdaq Biotechnology (BIB)

Delayed Data
As of Feb 05
 -2.78 / -6.47%
Today’s Change
Today|||52-Week Range

Investment Objective

The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index ®. The fund invests in securities and derivatives that ProShare Advisors believes, in combination, should have similar daily return characteristics as two times (2x) the daily return of the index. The index is a modified capitalization weighted index that includes securities of NASDAQ listed companies that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark ("ICB") which also meet other eligibility criteria determined by NASDAQ. The fund is non-diversified.

No recent news for ProShares Ultra Nasdaq Biotechnology.


1 month-39.77% 3 years+34.11%
3 months-42.00% 5 years+39.48%
1 year-42.05% Since inception+33.34%
Data through 02/06/2016

Quote Details

Previous close$42.94
Open day’s range39.10 – 42.92
Net asset value (NAV)40.12 (02/05/2016)
Daily volume974,364
Average volume (3 months)1,063,555
Data as of 4:00pm ET, 02/05/2016

Peer Comparisonvs. Trading-leveraged equity ETFs

Performance 5-yr return+39.48%+21.46%
Expense Gross exp ratio1.04%0.89%
Risk 5 year sharpe ratio1.06--
Net assets$470.9M$148.2M
Average market cap----
Average P/E----
Dividend / Share--0.19%


SFLA iPath® Long Extended S&P 500® TR Index...
ROLA iPath® Long Extended Russell 1000® TR ...
SSO ProShares Ultra S&P500


Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
-- 51.49%
-- 20.09%
-- 15.40%
-- 12.12%
-- 9.86%
CELG Celgene6.10%
-- 6.08%
-- 6.08%
BIIB Biogen5.96%
AMGN Amgen5.62%

Partner Offers